Investors Get Excited About Pfizer, BioNTech’s Coronavirus Vaccine Candidate
The path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of early-stage clinical data for two vaccine candidates and a rigorous new regulatory road map from the Food and Drug Administration.
On Tuesday, Inovio Pharmaceuticals Inc. INO, -26.79% shared the first data from the Phase 1 clinical trial for its coronavirus vaccine candidate, and the FDA issued guidance telling developers that approval requires a vaccine to reduce the risk of COVID-19 by 50% when compared with placebo. A day later, BioNTech BNTX, -3.89% and Pfizer Inc. PFE, +3.18% jumped into the fray, sharing that their experimental vaccine had generated neutralizing antibodies at a higher level than what has been reported in people recovering from a COVID-19 infection.
The news sent Inovio’s stock down and pushed up shares of BioNTech and Pfizer. Read more…………..
Chart Of The Day
ICARUS TV
A new report suggests that the Covid-19 vaccine being developed by Pfizer and BioNTech is showing positive results in current trials. CNBC’s Meg Tirrell reports.